Santi, Daniel V.
Ashley, Gary W.
Cabel, Luc
Bidard, Francois-Clement
Article History
Accepted: 2 January 2024
First Online: 18 January 2024
Declarations
:
: No external funding was used in the preparation of this work.
: DVS and GWA are co-founders of Prolynx, which is developing PLX038. LC and FCB will act as investigators in a clinical trial of PLX038, but have no financial interests in Prolynx. The authors have no other conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: DVS, GWA, LC, and F-CB all contributed to the concepts and conclusions described here. DVS did the initial writing of the commentary.